Investment
Features
FeesSafety
Academy
More
Pluang+

Compare YieldMax AI & Tech Portfolio Option Income ETF (GPTY) vs Pfizer Inc (PFE) Price & Performance

YieldMax AI & Tech Portfolio Option Income ETFTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

YieldMax AI & Tech Portfolio Option Income ETF vs Pfizer Inc — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $41.41, while Pfizer Inc trades at $25.07 (market cap $141.46B). The key difference: Pfizer Inc pays a 6.93% dividend while YieldMax AI & Tech Portfolio Option Income ETF pays none. Which is the better fit depends on your goals.

GPTYPFE
Sector
Income / Options OverlayHealth
52-Week High
$50.52$28.56
52-Week Low
$34.73$23.29
Market Cap
$141.46B
Volume
29,869,932
Enterprise Value
$192.12B
Dividend Yield
6.93%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax AI & Tech Portfolio Option Income ETF

GPTY trades at $41.41, down 3.97% on the day, with technical indicators showing a neutral to bearish bias. The ETF maintains a consistent weekly dividend distribution strategy, with recent payouts ranging from $0.30 to $0.38. Support and resistance levels cluster tightly around $43-$46, indicating potential for near-term consolidation. Recent news highlights focus on its option-income strategy and comparisons to peers like ULTY.

The outlook balances high yield potential against market volatility risks. Investment appeal centers on AI/tech exposure coupled with income generation, but reliance on semiconductor momentum and option premiums introduces volatility. Key risks include NAV erosion from the covered call strategy and sector concentration, requiring careful risk assessment for income-focused investors.

Pfizer Inc

Pfizer (PFE) trades at $24.25, down 0.94% on the day, with a bearish technical signal from moving averages. The company reported $62.58B in 2025 revenue and a net income margin of 11.83%, with recent quarterly earnings consistently beating expectations. A dividend of $0.43 per share is scheduled for payment on September 1, 2026. The stock's valuation includes a P/E of 18.51 and P/S of 2.19, while analyst consensus price target is $28.25.

Pfizer presents a mixed outlook with stable profitability and a strong dividend, but faces headwinds from patent expirations and competitive pressures. The stock offers value at current levels relative to analyst targets, though technical weakness and revenue declines from peak COVID-era sales pose near-term risks for investors.

Returns comparison

Trailing returns across standard periods

About YieldMax AI & Tech Portfolio Option Income ETF

GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.

Read more on GPTY

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE